Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Position Trimmed by Foundry Partners LLC

Foundry Partners LLC lowered its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,456 shares of the medical equipment provider’s stock after selling 103 shares during the period. Foundry Partners LLC’s holdings in Zimmer Biomet were worth $576,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of ZBH. CKW Financial Group lifted its holdings in shares of Zimmer Biomet by 11.7% during the fourth quarter. CKW Financial Group now owns 955 shares of the medical equipment provider’s stock valued at $101,000 after purchasing an additional 100 shares during the last quarter. Romano Brothers AND Company lifted its stake in Zimmer Biomet by 1.1% during the fourth quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider’s stock valued at $1,000,000 after buying an additional 102 shares in the last quarter. Dorsey & Whitney Trust CO LLC boosted its holdings in shares of Zimmer Biomet by 2.3% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider’s stock worth $485,000 after buying an additional 102 shares during the period. M&T Bank Corp increased its position in shares of Zimmer Biomet by 0.4% in the fourth quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider’s stock worth $2,834,000 after acquiring an additional 108 shares in the last quarter. Finally, Dakota Wealth Management raised its holdings in shares of Zimmer Biomet by 1.3% during the fourth quarter. Dakota Wealth Management now owns 9,620 shares of the medical equipment provider’s stock valued at $1,016,000 after acquiring an additional 122 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 4.6 %

Zimmer Biomet stock opened at $107.46 on Friday. Zimmer Biomet Holdings, Inc. has a one year low of $97.69 and a one year high of $129.50. The company’s fifty day moving average price is $107.32 and its two-hundred day moving average price is $107.21. The company has a market capitalization of $21.39 billion, a price-to-earnings ratio of 24.15, a PEG ratio of 1.95 and a beta of 1.04. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the prior year, the business posted $2.20 EPS. On average, analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.89%. Zimmer Biomet’s payout ratio is presently 21.57%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Raymond James decreased their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Stifel Nicolaus raised their target price on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Barclays dropped their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research report on Monday, February 10th. Truist Financial restated a “hold” rating and set a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $124.15.

Insiders Place Their Bets

In related news, SVP Lori Winkler sold 1,443 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.70% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.